Pancreatic cancer
FOENIX-BTC
A Phase 3, Randomized-Controlled, Open-Label, Multi- Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers.
Trial overview
Clinical Area
Medical Oncology
Disease
Gastric
Disease site
Gastrointestinal (GI)
Study Phase
III
Trial Identifiers
Registration number: NCT07710885
Principal Investigator(s)
··
··